Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Advanced liver cancer is difficult to treat, but with the addition of sorafenib (Nexavar) and then regorafenib, both doctors and patients are becoming more optimistic now that there are promising first- and second-line options. 

Bruix predicts that there will soon be an update to clinical practice guidelines to include regorafenib. Also, he is optimistic that after previous trial failures, the success of regorafenib will lead to even more research and developments for liver cancer.

View more from the 2016 World Congress on GI Cancer

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

ESMO Gastrointestinal Cancers Congress

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC). 

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment